JP2020532589A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020532589A5 JP2020532589A5 JP2020534804A JP2020534804A JP2020532589A5 JP 2020532589 A5 JP2020532589 A5 JP 2020532589A5 JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020534804 A JP2020534804 A JP 2020534804A JP 2020532589 A5 JP2020532589 A5 JP 2020532589A5
- Authority
- JP
- Japan
- Prior art keywords
- pyrazine
- amino
- naphthalene
- imidazole
- methylamino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762553320P | 2017-09-01 | 2017-09-01 | |
| US62/553,320 | 2017-09-01 | ||
| PCT/US2018/049081 WO2019046711A2 (en) | 2017-09-01 | 2018-08-31 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING IRE1 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020532589A JP2020532589A (ja) | 2020-11-12 |
| JP2020532589A5 true JP2020532589A5 (enExample) | 2021-10-21 |
Family
ID=65526075
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020534804A Pending JP2020532589A (ja) | 2017-09-01 | 2018-08-31 | Ｉｒｅ１阻害のための化合物および組成物 |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US11649237B2 (enExample) |
| EP (1) | EP3675858B1 (enExample) |
| JP (1) | JP2020532589A (enExample) |
| KR (1) | KR20200066301A (enExample) |
| CN (1) | CN111526877B (enExample) |
| AU (1) | AU2018326721B2 (enExample) |
| BR (1) | BR112020004226A2 (enExample) |
| CA (1) | CA3074139A1 (enExample) |
| IL (1) | IL272845B2 (enExample) |
| MX (1) | MX2020002322A (enExample) |
| SG (1) | SG11202001609RA (enExample) |
| WO (1) | WO2019046711A2 (enExample) |
| ZA (1) | ZA202001320B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7444458B2 (ja) * | 2018-09-21 | 2024-03-06 | 学校法人福岡大学 | プリオン病治療薬 |
| WO2020176761A1 (en) * | 2019-02-27 | 2020-09-03 | Optikira, LLC | Imidazolopyrazine compounds for ire1 inhibition |
| SG11202109194UA (en) * | 2019-02-27 | 2021-09-29 | Optikira Llc | Pyrazolopyridine compounds for ire1 inhibition |
| EP4192462A4 (en) * | 2020-08-07 | 2024-09-04 | Optikira LLC | PYRAZOLOPYRIDINE COMPOUNDS AND METHODS OF INHIBITING IRE1 USING THEM |
| US11884649B2 (en) * | 2020-11-13 | 2024-01-30 | The Regents Of The University Of California | IRE1α inhibitors and uses thereof |
| EP4460492A1 (en) * | 2022-01-07 | 2024-11-13 | (INSERM) Institut National de la Santé et de la Recherche Médicale | Compounds containing a hydroxyphenyl moiety and their use |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR057960A1 (es) * | 2005-12-02 | 2007-12-26 | Osi Pharm Inc | Inhibidores de proteina quinasa biciclicos |
| EP2283020B8 (en) | 2008-05-19 | 2012-12-12 | OSI Pharmaceuticals, LLC | Substituted imidazopyr-and imidazotri-azines |
| US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
| EP3799870A1 (en) * | 2010-04-05 | 2021-04-07 | Fosun Orinove Pharmatech, Inc. | Ire-1a inhibitors |
| EP2548877A1 (en) * | 2011-07-19 | 2013-01-23 | MSD Oss B.V. | 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors |
| MX2015003874A (es) * | 2012-09-26 | 2015-12-16 | Univ California | Modulacion de ire1. |
| WO2016004254A1 (en) | 2014-07-01 | 2016-01-07 | The Regents Of The University Of California | Combined modulation of ire1 |
| AU2017228405A1 (en) * | 2016-03-03 | 2018-10-18 | Cornell University | Small molecule IRE1-alpha inhibitors |
| WO2018102751A1 (en) | 2016-12-02 | 2018-06-07 | Quentis Therapeutics, Inc. | Ire1 small molecule inhibitors |
-
2018
- 2018-08-31 CA CA3074139A patent/CA3074139A1/en active Pending
- 2018-08-31 IL IL272845A patent/IL272845B2/en unknown
- 2018-08-31 EP EP18849820.8A patent/EP3675858B1/en active Active
- 2018-08-31 WO PCT/US2018/049081 patent/WO2019046711A2/en not_active Ceased
- 2018-08-31 SG SG11202001609RA patent/SG11202001609RA/en unknown
- 2018-08-31 AU AU2018326721A patent/AU2018326721B2/en active Active
- 2018-08-31 US US16/642,208 patent/US11649237B2/en active Active
- 2018-08-31 CN CN201880066168.9A patent/CN111526877B/zh active Active
- 2018-08-31 MX MX2020002322A patent/MX2020002322A/es unknown
- 2018-08-31 BR BR112020004226-9A patent/BR112020004226A2/pt not_active Application Discontinuation
- 2018-08-31 JP JP2020534804A patent/JP2020532589A/ja active Pending
- 2018-08-31 KR KR1020207009201A patent/KR20200066301A/ko not_active Ceased
-
2020
- 2020-02-28 ZA ZA2020/01320A patent/ZA202001320B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020532589A5 (enExample) | ||
| IL272845B1 (en) | Compounds and preparations for inhibiting ire1 | |
| RU2489426C2 (ru) | Производные аминопиразола | |
| JP2007519754A5 (enExample) | ||
| RU2455288C2 (ru) | Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ | |
| JP2013530240A5 (enExample) | ||
| JP2014511869A5 (enExample) | ||
| JP2020506946A5 (enExample) | ||
| RU2017121044A (ru) | Производные амидотиадиазола в качестве ингибиторов надфн-оксидазы | |
| JP2013507350A5 (enExample) | ||
| JP2010540462A5 (enExample) | ||
| JP2020515575A5 (enExample) | ||
| JP2012506446A5 (enExample) | ||
| JP2007514003A5 (enExample) | ||
| JP2021501179A5 (enExample) | ||
| RU2006145205A (ru) | Терапевтические соединения: пиридин в качестве каркаса | |
| JP2014508128A5 (enExample) | ||
| RU2012116877A (ru) | Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы | |
| RU2013133800A (ru) | Селективные к bcl-2 агенты, вызывающие апоптоз, для лечения рака и иммунных заболеваний | |
| JP2012503018A5 (enExample) | ||
| JP2007531757A5 (enExample) | ||
| RU2011134631A (ru) | Вызывающие апоптоз средства для лечения рака и иммунных и аутоиммунных заболеваний | |
| JP2008502700A5 (enExample) | ||
| JP2018522823A5 (enExample) | ||
| JP2020516671A5 (enExample) |